Literature DB >> 26503813

NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia.

D-C Liang1, C-P Yang2, H-C Liu1, T-H Jaing2,3, S-H Chen2,3, I-J Hung2, T-C Yeh1, T-H Lin4, C-L Lai4, C-Y Lai3, L-Y Shih3,4.   

Abstract

A recent study identified a variant of the NUDT15 gene (rs116855232 C>T) associated with intolerance to thiopurine in Korean patients with Crohn's disease. This study prompted us to substantiate the finding in a Taiwanese population. Four hundred and four children with acute lymphoblastic leukemia (ALL), and 100 adults with chronic immune thrombocytopenic purpura or localized lymphoma having normal bone marrow were examined. Two candidate gene approaches, pyrosequencing for NUDT15 and TaqMan assay for thiopurine methyltransferase (TPMT) genotyping (rs1142345 A>G), were performed. We showed a risk allele frequency of NUDT15 of 11.6% in children with ALL and 15.5% in adults. By contrast, the risk allele frequency of TPMT was only 1.6% in children with ALL and 0.5% in adults. The high frequency of risk variant for NUDT15, but not the very low frequency of risk variant for TPMT, was closely associated with the intolerance to mercaptopurine in children with ALL in Taiwan, contrast to that of European descent. In regard to NUDT15 polymorphism, the maximal tolerable daily doses of mercaptopurine in homozygotes, heterozygotes and wild-type groups were 9.4 mg m-2, 30.7 mg m-2 and 44.1 mg m-2, respectively. The outcomes did not differ significantly among the different genotypes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26503813     DOI: 10.1038/tpj.2015.75

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  22 in total

Review 1.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update.

Authors:  Ching-Hon Pui; William L Carroll; Soheil Meshinchi; Robert J Arceci
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

2.  Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.

Authors:  M V Relling; M L Hancock; J M Boyett; C H Pui; W E Evans
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

3.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.

Authors:  M V Relling; M L Hancock; G K Rivera; J T Sandlund; R C Ribeiro; E Y Krynetski; C H Pui; W E Evans
Journal:  J Natl Cancer Inst       Date:  1999-12-01       Impact factor: 13.506

4.  Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations.

Authors:  Jan-Gowth Chang; Long-Shyong Lee; Chih-Mei Chen; Mu-Chin Shih; Mei-Chen Wu; Fuu-Jen Tsai; Der-Cheng Liang
Journal:  Pharmacogenetics       Date:  2002-04

5.  Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese.

Authors:  K Kumagai; K Hiyama; S Ishioka; H Sato; Y Yamanishi; H L McLeod; F Konishi; H Maeda; M Yamakido
Journal:  Pharmacogenetics       Date:  2001-04

6.  Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia.

Authors:  D-C Liang; C-P Yang; D-T Lin; I-J Hung; K-H Lin; J-S Chen; C-C Hsiao; T-T Chang; C-T Peng; M-T Lin; T-K Chang; T-H Jaing; H-C Liu; L-Y Wang; T-C Yeh; S-T Jou; M-Y Lu; C-N Cheng; J-M Sheen; S-S Chiou; K-H Wu; G-Y Hung; R-L Chen; S-H Chen; S-N Cheng; Y-H Chang; B-W Chen; W-L Ho; J-L Wang; S-T Lin; Y-L Hsieh; S-C Wang; H-H Chang; Y-L Yang; F-L Huang; C-Y Chang; W-H Chang; K-S Lin
Journal:  Leukemia       Date:  2009-12-17       Impact factor: 11.528

7.  A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia.

Authors:  Suk-Kyun Yang; Myunghee Hong; Jiwon Baek; Hyunchul Choi; Wanting Zhao; Yusun Jung; Talin Haritunians; Byong Duk Ye; Kyung-Jo Kim; Sang Hyoung Park; Soo-Kyung Park; Dong-Hoon Yang; Marla Dubinsky; Inchul Lee; Dermot P B McGovern; Jianjun Liu; Kyuyoung Song
Journal:  Nat Genet       Date:  2014-08-10       Impact factor: 38.330

8.  Reversal of methylmercaptopurine ribonucleoside cytotoxicity by purine ribonucleosides and adenine.

Authors:  E H Stet; R A De Abreu; J P Bökkerink; L H Lambooy; T M Vogels-Mentink; J J Keizer-Garritsen; F J Trijbels
Journal:  Biochem Pharmacol       Date:  1995-01-06       Impact factor: 5.858

9.  Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase.

Authors:  E Y Krynetski; N F Krynetskaia; Y Yanishevski; W E Evans
Journal:  Mol Pharmacol       Date:  1995-06       Impact factor: 4.436

10.  Triple intrathecal therapy alone with omission of cranial radiation in children with acute lymphoblastic leukemia.

Authors:  Hsi-Che Liu; Ting-Chi Yeh; Jen-Yin Hou; Kuan-Hao Chen; Ting-Huan Huang; Ching-Yi Chang; Der-Cherng Liang
Journal:  J Clin Oncol       Date:  2014-05-12       Impact factor: 44.544

View more
  39 in total

1.  DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes.

Authors:  Hee Young Ju; Ji Won Lee; Hee Won Cho; Ju Kyung Hyun; Youngeun Ma; Eun Sang Yi; Keon Hee Yoo; Ki Woong Sung; Rihwa Choi; Hong Hoe Koo; Soo-Youn Lee
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

Review 2.  Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.

Authors:  Rochelle R Maxwell; Peter D Cole
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

3.  The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia.

Authors:  Takaya Moriyama; Rina Nishii; Ting-Nien Lin; Kentaro Kihira; Hidemi Toyoda; Nersting Jacob; Motohiro Kato; Katsuyoshi Koh; Hiroto Inaba; Atsushi Manabe; Kjeld Schmiegelow; Jun J Yang; Hiroki Hori
Journal:  Pharmacogenet Genomics       Date:  2017-06       Impact factor: 2.089

4.  Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia.

Authors:  Rihwa Choi; Insuk Sohn; Min-Ji Kim; Hye In Woo; Ji Won Lee; Youngeun Ma; Eun Sang Yi; Hong Hoe Koo; Soo-Youn Lee
Journal:  Br J Clin Pharmacol       Date:  2019-05-27       Impact factor: 4.335

Review 5.  [Significance of NUDT15 gene in individualized treatment with 6-mercaptopurine in children with acute lymphoblastic leukemia].

Authors:  Jing He; Ling Liu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2019-01

Review 6.  Association of NUDT15 c.415C>T allele and thiopurine-induced leukocytopenia in Asians: a systematic review and meta-analysis.

Authors:  A L Zhang; J Yang; H Wang; J L Lu; S Tang; X J Zhang
Journal:  Ir J Med Sci       Date:  2017-05-03       Impact factor: 1.568

7.  Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry.

Authors:  Takaya Moriyama; Yung-Li Yang; Rina Nishii; Hany Ariffin; Chengcheng Liu; Ting-Nien Lin; Wenjian Yang; Dong-Tsamn Lin; Chih-Hsiang Yu; Shirley Kham; Ching-Hon Pui; William E Evans; Sima Jeha; Mary V Relling; Allen Eng-Juh Yeoh; Jun J Yang
Journal:  Blood       Date:  2017-06-28       Impact factor: 22.113

8.  Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia.

Authors:  Y Tanaka; H Nakadate; K Kondoh; K Nakamura; K Koh; A Manabe
Journal:  Pharmacogenomics J       Date:  2017-04-18       Impact factor: 3.550

9.  Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients.

Authors:  Natalia Sutiman; Sylvia Chen; Khoon Lin Ling; Sai Wei Chuah; Wai Fook Leong; Vinayak Nadiger; Madeline Tjai; Chris San Choon Kong; Brian John Schwender; Webber Chan; Hang Hock Shim; Wee Chian Lim; Chiea Chuen Khor; Yin Bun Cheung; Balram Chowbay
Journal:  Pharmacogenomics       Date:  2017-12-06       Impact factor: 2.533

Review 10.  [Research advances in pharmacogenomics of mercaptopurine].

Authors:  Xiao-Xiao Chen; Shu-Hong Shen
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.